Axbio International Limited has submitted an updated application for listing, with CICC and SPDB International as joint sponsors. The company specializes in integrated circuit biotechnology, leveraging core technologies such as chip design, synthetic biology, electrochemical microfluidics, and artificial intelligence to develop a new generation of electrochemical detection platforms, driving innovation in life science tools and the diagnostics industry. In terms of technological barriers, the company has secured 55 global patent authorizations, with an additional 40 patent applications in progress. The two co-founders are graduates of Tsinghua University, Stanford University, and Saint Petersburg State University, respectively, and are inventors of over a hundred global patents, having previously led core research and development at multinational pharmaceutical companies and Silicon Valley tech firms. Over 70% of the R&D team holds master's degrees or higher, bringing extensive industrial experience. The product pipeline includes the microarray chip analyzer AxiLona EL-100, two EL-NGS sequencers, and accompanying reagent kits. Among these, the EL-100 has obtained EU CE and China Medical Device Registration certificates, with protein detection functionality already designed. The flagship product, the AXP-100 sequencer, has also successfully completed type testing. This device features the world's first 300-millimeter, 65-nanometer process Bio-CMOS chip, integrating over a million parallel nanopore detection units on a single chip. This enables ultra-high-throughput molecular signal acquisition, providing foundational data support for AI analysis and multi-omics applications while significantly reducing detection costs. Its portability and ease of use make it highly suitable for distributed primary healthcare settings. Financially, the company achieved revenue of $1.21 million in 2025, representing a 153% year-on-year increase. Adjusted net loss narrowed from $14.66 million in 2024 to $12.66 million, indicating a clear trend of operational improvement. The company has established collaborations with globally renowned research institutions, industry partners, and multiple hospitals, with initial progress in commercial expansion. Axbio deeply integrates integrated circuits and biotechnology, using advanced life science tools as a vehicle and combining AI and bioinformatics analysis capabilities, demonstrating an innovative paradigm akin to "the Tesla of precision medicine." Just as Tesla brought autonomous driving from the laboratory to the masses, with hardware vehicles and software FSD combining to form intelligent entities in the new energy sector, the life science industry urgently requires intelligent entities capable of producing vast amounts of multi-omics molecular detection data at low cost. Axbio is accelerating its "multi-platform, multi-omics" three-dimensional strategic layout, integrating various technological platforms and multi-omics data analysis capabilities to facilitate the transition of precision medicine from tertiary hospitals to community clinics. As adoption scales, the company aims to expand the cognitive boundaries of existing applications and foster entirely new paradigms for life science research and clinical scenarios, empowering the broader health industry to ascend spirally. This will also drive sustained business growth for the company, steadily ushering it into a new phase of high-quality development.
Comments